支原体预防与清除利器，PlasmocinTM prophyl

支原体预防与清除利器，支原体清除，支原体预防，Mycoplasma Removal Agent
产品优势：1，预防支原体、细菌、真菌污染
2，只需2周即可清除支原体污染
3，不会影响细胞本身代谢
4， 不会重新感染（从其他细胞释放的）支原体

抗微生物污染试剂

Plasmocin™

Mycoplasma Removal Agent

Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria.
Plasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures.

Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks.
The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are completely absent in eukaryotic cells.

Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.

Plasmocin™ prophylactic
2.5 mg/ml (Plasmocin™ Prophylactic)

货号：ant-mpp
支原体预防报价：1372元/25 mg (10 x 1 ml)

Plasmocin™ treatment

货号：ant-mpt
25 mg/ml (Plasmocin™Treatment)
支原体清除报价：2114元/50 mg (2 x 1 ml)

Comparison of the most common anti-mycoplasma agents [1-3]

对照表

Product	Supplier	Treatment	Ease of use	Efficacy	Cytotoxicity	Resistance
BM-Cyclin	Roche	3 weeks	-	+++	+	+/-
Ciprobay	Bayer	12 to 20 days	+	++	+/-	+
MRA	ICN	1 to 2 weeks	+	++	+/-	+
Plasmocin	InvivoGen	2 weeks	+	+++	+/-	-

Antibiotics commonly used in cell culture are inactive on mycoplasma (e.g. penicillins and streptomycin). Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA.
Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin (Roche) contains a macrolide and a tetracycline, Ciprobay (Bayer, available only with a prescription) and MRA (ICN) are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected[1].

1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34.
2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A(11-12):708-10
3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A(5):344-7

参考文献：

Recent articles using Plasmocin™

• 2012 - J Virol Methods., 187(2):234-7
  Mycoplasma removal: Simple curative methods for viral supernatants.
  Baronti C, Pastorino B, Charrel R, de Lamballerie X
• 2011 - Mol Pharmacol., 80(6):1066-75
  Ca2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy.
  Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T
• 2011 - J Immunol., 186(12):6822-6829
  Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.
  Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S
• 2012 - J. Biol. Chem., 287: 8082 - 8091
  Loss of lysosomal ion channel transient receptor potential channel mucolipin-1 (TRPML1) leads to cathepsin B-dependent apoptosis.
  Colletti GA, Miedel MT, Quinn J, Andharia N, Weisz OA, Kiselyov K
• 2012 - Immunity, 36(3):464-476
  An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages.
  Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C

• Plasmocin Prophylactic (2.5 mg/ml)：用以预防支原体污染，通常使用浓度2.5 至 5 µg/ml 。

• Plasmocin Treatment (25 mg/ml)：用以清除支原体，通常使用浓度 25 µg/ml，处理两个星期。

在T75中，可处理 25 个细胞系。
Plasmocin™为黄色液体，无菌，通过细胞培养检测：

- 25 mg/ml (Plasmocin™Treatment)

- 2.5 mg/ml (Plasmocin™ Prophylactic)
订购
Plasmocin™ prophylactic
内容摘要 预防支原体污染
货号 ant-mpp
单位规格 25 mg (10 x 1 ml)
价格 ¥ 1378

Plasmocin™ treatment
内容摘要 清除支原体污染
货号 ant-mpt
单位规格 50 mg (2 x 1 ml)
价格 ¥ 2119

与其它抗支原体试剂相比，Plasmocin™可同时作用于细胞外与细胞内的支原体。这一优点得益于Plasmocin™其中的一个组份可被转运到哺乳动物细胞内，从而确保Plasmocin™处理后的细胞不会因为细胞释放出来的支原体而再此污染。

目前在所有检测的动物细胞中，即使提高至五倍工作浓度，细胞代谢并没有出现明显变化。

多组独立实验结果显示，按说明书处理后的细胞培养液中不含抗性支原体突变株，证明试剂不会引起支原体抗性株。

Plasmocin™也可作用于低浓度的青霉素，链霉素抗性革兰氏阳性和革兰氏阴性菌。

包括胚胎干细胞，杂交瘤细胞和反转录病毒包装细胞在内的多类细胞的支原体污染，均可被Plasmocin™清除。

抗支原体污染常用试剂比较[1-3]